MXDHF News Alert Mdxhealth Sa (MXDHF) 5.6500 12/25/2014 14:4

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mdxhealth Sa (MXDHF) 5.6500 $MXDHF

Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST

VIVO: 16.68 (-0.02), TMO: 126.79 (+0.13), EXAS: 27.60 (+0.39)

MDxHealth to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
GlobeNewswire - Wed Nov 12, 2:35AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that CEO, Dr. Jan Groen, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, which is being held on November 20, 2014, at Westin Grand Central in New York. Dr. Jan Groen will make the Company's presentation at 1:30 PM Eastern Daylight Time. The presentation will be posted under the investor tab of the MDxHealth website (http://mdxhealth.com/investors/shareholder-information) after the conference.

MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST

EXAS: 27.60 (+0.39)

MDxHealth Provides Third Quarter 2014 Business Update
GlobeNewswire - Tue Nov 04, 1:08AM CST
MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.

MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
GlobeNewswire - Fri Oct 10, 1:11AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.

MDxHealth Presents Results from Epigenetic Test to Identify Prostate Cancer Aggressiveness at the European Association of Urology Meeting 2014
GlobeNewswire - Tue Oct 07, 1:09AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from a validation study of an epigenetic test to predict prostate cancer (PCa) aggressiveness at the European Association of Urology, Section Urological Research meeting in Glasgow, UK (October 9-11, 2014).

MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014
GlobeNewswire - Tue Sep 23, 1:19AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.

MDxHealth to Participate in the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Mon Sep 08, 9:33AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.

MDxHealth Reports First Half Year 2014 Results
GlobeNewswire - Thu Aug 21, 1:12AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results of the first-half year ended June 30, 2014.

MDxHealth ConfirmMDx Biomarker Associated with the Risk of Recurrence for Early Stage Prostate Cancer Patients
GlobeNewswire - Mon Aug 18, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that one of the ConfirmMDx for Prostate Cancer epigenetic genes is independently associated with risk of recurrence in patients with early prostate cancer (PCa). The results from this study, published in The Journal of Urology [The Journal of Urology (2014), doi: 10.1016/j.juro.2014.04.082], suggest that epigenetic analysis could play a clinical role in identifying patients who have a slow growing cancer eligible for active surveillance from those with a higher risk of recurrence who may benefit from a more aggressive therapeutic approach.

MDxHealth Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
GlobeNewswire - Thu Aug 14, 1:07AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx for Prostate Cancer test.
ANCI: 2.21 (-0.11)

MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
GlobeNewswire - Tue Aug 12, 2:05AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard(R) stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed to Exact Sciences in July 2010. Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.

ConfirmMDx Studies Highlighted by Elsevier, Publisher of The Journal of Urology(r)
GlobeNewswire - Tue Jul 22, 1:08AM CDT
Underscores Importance of Recent Confirmatory Clinical Validation Results Leading to Medicare Reimbursement Milestone

MDxHealth and Miraca Life Sciences Announce Agreement to Promote ConfirmMDx for Prostate Cancer
GlobeNewswire - Wed Jul 02, 1:06AM CDT
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has entered into an agreement with Miraca Life Sciences (MLS), the nation's largest independent anatomic pathology lab, to promote MDxHealth's ConfirmMDx for Prostate Cancer test. Serving more than 5,500 patients each day, Miraca Life Sciences is a national leader in providing academic-caliber pathology services in the fields of dermatology, hematology, gastroenterology and urology.

MDxHealth Reports Fourth Quarter and Fiscal Year 2013 Results
GlobeNewswire - Thu Feb 27, 1:05AM CST
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced results for the fourth quarter and the fiscal year ended December 31, 2013. This year the company has changed its reporting currency to U.S. Dollars, while keeping its functional currency in Euros.
BAS: 7.30 (-0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 158

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading
Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 91

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
AT&T's Dec. 8 UBS Chat Puts Stankey's Updates on Watch

Updated Category News Views 202

A Small Slot With a Big Audience A calendar entry can still matter when the man holding the microphone runs AT&T. John Stankey, AT&T chairman and chief executive, is scheduled for a fireside chat at the UBS Global Media and Communications Conference on Tuesday, Dec. 8, beginning at 8:15 a.m. Eastern time. The company says the event will be webcast live through its...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 0

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 39

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
PinnacleQM Makes Its Enterprise Case More Visible

Updated Category News Views 118

Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 77

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading

Top 5 Most Recently Viewed Articles

BD Settles SEC Investigation While Strengthening Operations

Updated Category News Views 215

BD Reaches Settlement with the SEC BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System. Key Details of the Resolution The...

Continue Reading
Seizing the Managed Detection and Response Market Opportunity

Updated Category News Views 232

Unlocking the Managed Detection and Response Market Potential Middleton, Massachusetts – QKS Group, a leading market intelligence and advisory firm, recently released an insightful report on the global Managed Detection and Response (MDR) Market. This comprehensive analysis targets industry leaders eager to tap into a rapidly growing sector. According to their findings,...

Continue Reading
Expanding Horizons: Coldwell Banker's Venture into Africa

Updated Category News Views 94

Coldwell Banker Real Estate's New Milestone Coldwell Banker Tanzania and Zanzibar have officially joined the growing network of Coldwell Banker Real Estate LLC, marking an exciting expansion into Africa. This new master franchise embodies the brand’s ongoing commitment to deliver top-tier real estate services on an international scale. Seizing Growing Markets The real...

Continue Reading
Automotive Grade Linux Unveils SoDeV Platform for Advancements

Updated Category News Views 289

Automotive Grade Linux Introduces SoDeV for Software Defined Vehicles In an exciting development for the automotive industry, Automotive Grade Linux (AGL) has launched SoDeV, an open-source reference platform aimed at significantly enhancing the development of Software Defined Vehicles (SDVs). This innovative platform allows developers to focus on software-first...

Continue Reading
Exploring Promising Tech Stocks Ahead of Future Opportunities

Updated Category News Views 257

Opportunity in Oversold Tech Stocks The information technology sector is witnessing a notable shift, with several stocks currently considered undervalued. These oversold stocks represent potential opportunities for savvy investors looking to capitalize on future growth. By focusing on these stocks, investors can identify undervalued companies that have the potential for...

Continue Reading